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ABSTRACT 
Cyclophosphamide (CP) is a widely used antineoplastic drug, it is used for the treatment of several malignancies. However, upon 
treatment, it induces severe toxicity due to its oxidative stress capability  In this study we evaluate the cytoprtective efficacy of 
Arisaema leschnaultii blume (AL) against cyclophosphamide induced hepatotoxicity in tumor bearing mice due to its antioxidant 
property. Female Swiss albino mice were used. Group I-Naive control, Group II-DAL bearing, Group III-DAL + CP, Group IV-  
DAL + AL + CP,  Group V- DAL + AL + CP, Group VI-DAL + Amifostine + CP. CP induced hepatic damage as indicated by 
significant elevation (P < 0.05) in aspartate aminotransferase, organ weight, and evidence by the histological study. CP also induced 
hepatic oxidative stress as indicated by significant elevation (P < 0.05) in malondialdehyde content, hydrogen peroxide (H2 O2 ) 
generation, nitrite level, and the level of glutathione (GSH) peroxidase crashed in the CP treated group. AL enhanced the antioxidant 
defense system as indicated by elevation in GSH level, catalase activity, and GSH-S-transferase activity and by inhibiting MDA. 
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INTRODUCTION 
Cyclophosphamide (CP) is a cytotoxic alkylating agent  
that has been in clinical use for over 50 years and it is 
effective in the treatment of neoplastic diseases such as 
solid tumors and lymphomas as well as nonneoplastic 
diseases such as rheumatoid arthritis and systemic 
lupus erythematosus.
1
 However, the clinical use of 
CPA has been limited due to its ability to damage 
normal tissues which usually resulted in multiple organ 
toxicity mainly in the heart, testes, and urinary 
bladder.
2 
Hepatotoxicity is a major side effect of CPA 
as it is metabolized principally within the hepatocytes 
by hepatic microsomal cytochrome p450 mixed 
function oxidase system to produce its two active 
metabolite phosphoramide mustard and acrolein.
3,4
 
Phosphoramide is associated with its 
immunosuppressive and antineoplastic effect, while 
acrolein is associated with its toxic effect.
5,6
 Studies 
have suggested that oxidative stress is associated with 
its hepatotoxic effect.
7
 CPA toxicity results from 
acrolein binding to cellular antioxidant nucleophiles 
such as glutathione (GSH) resulting in the depletion of 
the antioxidant defense system and it also initiates lipid 
peroxidation(LPO).
8
 
Cytoprotective agents offer opportunities to reduce the 
treatment-related toxicity of anticancer therapy and 
perhaps to increase the dose and dose intensity of 
radiation and chemotherapy.
9
 Over 4000 cytoprotective 
agents were studied i.e.drde-07, herbal extract, Vit C, 
Vit E etc.
10
 The plant, Arisaema leschenaultii (Family 
Araceae) is a small tree distributed in the greater part of 
India on the hills of Assam, Karnataka, Kerala and 
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Tamilnadu has the antioxidant activity.
11
 In this study 
we examine the cytoprtective efficacy of Arisaema 
leschnaultii blume against cyclophosphamide induced 
hepatotoxicity in tumor bearing mice. 
MATERIALS AND METHODS 
MATERIALS 
Chemicals   
Cyclophosphamide, amifostine, DTNB, alanine 
aminotransferas, alkaline phosphate, aspartase,bovine 
serum albumin,Bradford reagent, disodium hydrogen 
phosphate, disodium EDTA, EDTA, ethyl alcohol, 
formaldehyde, glacial meta phosphoric acid. 
Glutathione, lactate dehydrogenase, potassium chloride, 
ripa buffer, sodium chloride,tris buffer, sodium 
dihydrogen phosphate, thiobarbituric acid, tris 
carboxylic acid. 
Animals 
Female Swiss albino mice (25-30 g) were obtained 
from the central animal facility of Jiwaji University 
Gwalior and were maintained in polypropylene cages 
on rodent pellet condition of controlled temperature 
(22±2 
o
C) and acclimatized to 12/12 h light/dark cycle. 
Free access to food and water were allowed until 2h 
before the experiment. The care and maintenance of the 
animals were as per the approved guidelines of the 
“Committee for the purpose of control and supervision 
of experiments on animals (CPCSEA)”. Food and 
water were provided 2h after the experiment. All 
experiments on animals were conducted according to 
the guidelines of establishment’s ethical committee on 
animal experimentation. 
 Plant Extraction 
Ethanol extraction For preparation of ethanol extract 
10g of root powder was dissolved in 100ml of ethanol 
and kept at 270C for two days and filtered through 
Whatmann no. 1 filter paper. The filtrate was then 
allowed to evaporate to get concentrated filtrate which 
was again reconstituted in small volumes of same 
solvent. The solvent was air-dried and the extract was 
weighed. 
METHODS 
Induction of Tumor  
5×10
6
 cells of Dalton’s lymphoma (DAL) were injected 
in the peritoneal cavity of each animal on day 0. 
Cyclophospamide (CP) (200mg/kg) was administered 
intraperitoneally (i.p) to groups of mice on day 3 after 
inoculation of Dalton’s Lymphoma (DAL) for 7 
consecutive days. AL (100mg/kg, 200mg/kg) and 
Amifostine (300mg/kg) was given orally 30 min prior 
to CP administration for 12 days. . Group I-Naive 
control, Group II-DAL bearing, Group III-DAL + CP, 
Group IV- DAL + AL + CP, Group V- DAL + AL + 
CP, Group VI-DAL + Amifostine + CP. The body 
weights of the animals were recorded daily up to 12 
days and after 12 days animals were anaesthetized with 
ether for collection of blood from orbital sinus, and 
then sacrificed by cervical dislocation for the removal 
of vital organ. Various haematological and biochemical 
analysis were carried out. 
Biochemical estimation  
Blood biochemistry, hepatic glutathione and hepatic 
MDA were estimated after the exposure. Hepatic 
Glutathione concentration of tissue was assayed 
according to method. Blood GSH was estimated by the 
method 
12
 Beutler et al. (1963).  In brief, 150 milligram 
of tissue was homogenized in 0.02 M EDTA buffer (pH 
8.0) and 50% TCA was added to it. Supernatant was 
mixed with 0.4 M tris buffer (pH 8.9), and 0.01 M 
DTNB (5, 5'- Dithio- bis- (2-nitrobenzoic acid) and 
absorbance was read at 410 nm 
13
. Hepatic lipid 
peroxidation was determined by measuring the level of 
thiobarbituric acid substance (TBARS) formed, using 
thiobarbituric acid (TBA), according to the method 
14
. 
Blood Hb, RBC and WBC were analyzed by using 
Bechman Coulter Analyzer (USA). SGPT, SGOT, ALP 
and total protein concentrations were estimated by 
using kits (Ecoline, Merck).  
Thiol assay 
The reaction mixture containing 900   µL 2mM Na 2 
EDTA in 0.2M Na2HPO4, 20   µL 10mM DTNB in 
0.2M Na2HPO4 and 100   µL serum was incubated at 
room temperature for 5 min; the absorbance was read at 
412 nm. Appropriate sample and reagent blanks were 
prepared simultaneously and the respective absorbance 
was noted. Corrected absorbance values were used to 
calculate serum protein thiol content using a molar 
extinction coefficient of 1600/M/cm and values were 
expressed as mM. The calibration curve was produced 
using GSH dissolved in phosphate-buffered saline 
(PBS) 
15
 
GST assay 
One mL of reaction mixture containing 850   µL of 
0.1M phosphate buffer, pH 6.5, 50  µL 20mM CDNB 
(1-chloro 2,4-dinitrobenzene) and 50  µL 20mM GSH 
was pre-incubated at 37
o
C for 10min. Reaction was 
started by adding 50  µL serum and GST activity was 
assayed kinetically. Reaction was followed at one 
minute intervals for five minutes by measuring the 
absorbance at 340nm. GST was determined by using a 
molar extinction coefficient of 9.6/mM/cm and GST 
activity was expressed as IU/L. 
16
 and (Harvey, J.W. et 
al., 1982) 
 MDA assay 
The reaction mixture containing 1mL 0.67% 
thiobarbituric acid (TBA), 1 mL 20% tricarboxylic acid 
(TCA), and 100   µL serum was incubated at 100
 o
C for 
20 min and centrifuged at 12,000 rpm for 5 min. The 
absorbance of the supernatant was read at 532 nm and 
MDA concentration was determined by using a molar 
extinction coefficient of 1.56×10
 5
 /M/cm and the 
values were expressed as mM. 
17
 
Determination of SOD aaand cataase  
The determination of hepatic superoxide dismutase 
(SOD) activity by measuring the inhibition of 
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autooxidation of epinephrine at pH 10.2 and 30 °C. 
SOD activity was expressed in U/mg protein. Hepatic 
catalase activity was determined according to the 
method of 
18
. by measuring the reduction of dichromate 
in acetic acid to chromic acetate at 570 nm. Catalase 
activity was expressed as µmol H2O2 
consumed/min/mg protein. 
Protein Expression (Western Blotting)  
20% tissue was homogenated in RIPA lysis buffer 
(Sigma, U.S.A.). Equal amounts of proteins (quantified 
by Bradford assay) were mixed with Laemmli sample 
buffer, resolved on 12% SDS-poly-acrylamide gel and 
transferred to polyvinylidene difluoride membranes 
(Millipore). The membranes were blocked with a buffer 
containing 5% non-fat skimed milk powder in PBST 
(1×PBS, 0.2% Tween 20) at 4
o
C for 1hour, and 
subsequently incubated in the same buffer containing 
primary caspase-3 antibodies in 1:2000 dilution (Santa 
Cruz Biotechnology, Santa Cruz, CA) for overnight at 
4
o
C and then membrane was washed by PBS-T and 
incubated for secondary antibodies for 1 hour. The 
Proteins bands were identified by using an enhanced 
chemiluminescence detection system in accordance 
with the manufacturer’s instructions (ECL or ECL, 
Amersham Biosciences). 
 Histopathological Studies 
Liver tissues of mice were removed and washed with 
normal saline. The cleared tissue was fixed in 10% 
natural buffered formalin solution (pH 7.0-7.2). After 
proper fixation tissue was processed for dehydration in 
ascending grade of ethanol, clearing with toluene, 
followed by impregnation in paraffin wax, then 
sections of 5 µ in thickness were cut with help of semi-
automatic rotary microtome. Sections were stained with 
hematoxyline. Stained paraffin sections of liver were 
examined under phase contrast microscope (Lieca 
DMLB) and photomicrographs were taken. 
Representive area were captured and analyzed with the 
help of Lieca Qwin V3 digital image processing and 
analysis system. 
 Hepatic Apoptosis Determination (TUNEL 
Assay) 
Apoptosis was measured by the identification of 
apoptotic nuclei in sections of liver by fragment end 
labeling of DNA (Apoptosis detection kit, Chemicon, 
USA). In, brief, endogenous peroxidase activity was 
inactivated by 3% hydrogen peroxides. The DNA 
fragments were allowed to bind an antidigoxigenin 
antibody that was conjugated to a peroxidase. 
Diaminobenzidine (DAB) was applied to develop dark 
brown colour and then the slides were counterstained 
with haematoxylin. All fields in each sample were 
evaluated for positive stained liver cell. The results 
were expressed as the number of positive stained cells 
per high-power field. 
 Organ to Body Weight Indices (OBWI)  
After sacrificing the animals, Liver was removed and 
the washed free of extraneous materials and weighed. 
The organ to body weight indices (OBWI) were 
calculated as per the formula given below: 
 
 Statistical Analysis 
Statistical evaluations were made using one-way 
ANOVA followed by Dunnet’s test. A probability of 
0.05 and less was taken as statistically significant. The 
analyses were carried out using sigma stat for windows 
version 2.03 (SPSS Inc.USA).  
RESULTS 
 
P<0.05, as compared to control group (One Way 
ANOVA followed by Dunnett’s t test). 
Figure 1: Effect of pretreatment of AL (100mg/kg), AL 
(200mg/kg) and Amifostine on body weight of CP 
treated tumor bearing mice. 
 
 
*P<0.05, as compared to control group (One Way 
ANOVA followed by Dunnett’s t test). 
Control values for liver OBWI = 8±0.06 
Figure 2: Effect of pretreatment of AL (100mg/kg), AL 
(200mg/kg) and Amifostine on liver organ body weight 
indices (OBWI). 
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*P<0.05, as compared to control group (One Way ANOVA 
followed by Dunnett’s t test). 
Control values for WBC=7.4 ± 0.7 × 103 cell/µl; RBC=8.4× 
106 cells/µl; Hb=13.2 ± 0.4 g/dl 
Figure 3: Effect of pretreatment of AL (100mg/kg), AL 
(200mg/kg) and Amifostine on % WBC,RBC and Hb 
levels in CP treated tumor bearing mice. 
 
*P<0.05, as compared to control group (One Way ANOVA 
followed by Dunnett’s t test) 
Control values for Blood GSH=0.075±0.05 mg/dl. 
Figure 4: Effect of pretreatment of AL (100mg/kg), AL 
(200mg/kg) and Amifostine on blood GSH 
(µmoles/mg) levels in SM treated tumor bearing mice. 
 
*P<0.05, as compared to control group (One Way 
ANOVA followed by Dunnett’s t test). 
Control values for SGPT = 25±1.01 IU/L; SGOT = 
26.1±1.02 IU/L; ALP = 29.2±2.1 IU/L 
Figure 5: Effect of pretreatment of AL (100mg/kg), AL 
(200mg/kg) and Amifostine on SGPT (IU/L), SGOT  
(IU/L) and ALP (IU/L) levels in CP treated tumor 
bearing mice. 
 
*P<0.05, as compared to control group (One Way ANOVA 
followed by Dunnett’s t test) 
Control values for GST= 0. 248±0.05 IU/L; Total thiol = 
0.193±0.07mM; MDA = 0.22±0.08×10-3mM 
Figure 6: Effect of pretreatment of AL (100mg/kg), AL 
(200mg/kg) and Amifostine on % plasma GST (IU/L), 
total thiol (mM) and MDA (mM) levels in CP treated 
tumor bearing mice. 
 
*P<0.05, as compared to control group (One Way ANOVA 
followed by Dunnett’s t test). 
Control values for GSH = 7.2±0.4 µmoles/gm of tissue 
Figure 7:  Effect of pretreatment of AL (100mg/kg), 
AL (200mg/kg) and Amifostine on hepatic % GSH 
(µmoles/mg) levels in CP treated tumor bearing mice. 
 
*P<0.05, as compared to control group (One Way ANOVA 
followed by Dunnett’s t test). 
Control value for MDA = 4.43 ± 0.5 nmol/gm of tissue. 
Figure 8: Effect of pretreatment of AL (100mg/kg), AL 
(200mg/kg) and Amifostine on hepatic % MDA 
(nmol/mg protien) levels in SM treated tumor bearing 
mice. 
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*P<0.05, as compared to control group (One Way ANOVA 
followed by Dunnett’s t test). 
Control value for CATALASE = 72.12 ± 0.7 U/mg protein. 
Figure 9: Effect of pretreatment of AL AL (100mg/kg), 
AL (200mg/kg) and Amifostine on catalase (U/mg 
protein) levels in CP treated tumor bearing mice. 
 
 
*P<0.05, as compared to control group (One Way 
ANOVA followed by Dunnett’s t test). 
Control value for TOTAL PROTEIN = 10.02 ± 0.37 
U/mg protein. 
Figure 10: Effect of pretreatment of AL AL 
(100mg/kg), AL (200mg/kg) and Amifostine on total 
protein (U/mg protein) levels in CP treated tumor 
bearing mice. 
 
*P<0.05, as compared to control group (One Way ANOVA 
followed by Dunnett’s t test). 
Control value for SOD = 45.41 ± 0.67 U/mg protein. 
Figure 11: Effect of pretreatment of AL AL 
(100mg/kg), AL (200mg/kg) and Amifostine on SOD 
(U/mg protein) levels in CP treated tumor bearing 
mice. 
 
 
GROUP-1 DAL 
GROUP-2 DAL + CP 
GROUP-3 DAL + CP + AL 
GROUP-4 DAL + CP + AL 
GROUP-5 DAL + CP + AMIFOSTINE 
GROUP-6 CONTROL 
Figure 12: Effect of pretreatment of AL (100mg/kg), 
AL (200mg/kg)  and Amifostine on Caspase-3  protein 
expression in CP treated tumor bearing mice.
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(A) Control                                             (B) DAL                                         (C) DAL+CP 
 
(D) DAL+AL+CP                                   (E) DAL+AL+CP                             (F) DAL+ Ami + CP 
Figure 13 (A-F): Photomicrographs of CP administered (200 mg/kg, pc), AL (100mg/kg), AL (200mg/kg)  on mice 
liver and other treatment 
 
Figure 14 (A-F): Effect of pretreatment of AL (100mg/kg), AL (200mg/kg) and Amifostine on hepatocytes in CP 
treated tumor bearing mice (A) Control; (B) DAL (C) DAL+AL+CP; (D) DAL+ AL+ CP; (E) DAL+AL+CP ; (F) 
DAL+ Amifostine+CP 
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As per the literature the estimated cytotoxic dose of 
cyclophospamide is 200 mg/kg. All the DAL bearing 
mice treated with 200mg/kg of CP to induce 
hepatotoxicity.  
In fig1 the percentage increase in body weight was 
significant (p<0.05) in treated groups compared to naive 
group.  Body weight was increased significantly in DAL 
bearing mice (p<0.05) compared to naive group where 
as in CP treated mice body weight was significantly 
decreased compare to naïve control group. Body weight 
was not significantly changed by pretreatment of AL 
(100mg/kg, 200mg/kg) and Amifostine in CP treated 
tumor bearing mice compared to naïve control mice. No 
significant change was found in liver weight in any 
groups compared to control group (Figure2).   
Figure 3 shows,   WBC, RBC count and Hemoglobin 
level after 200 mg/kg of CP and other treatments in 
tumor bearing mice. There was significant (p<0.05) fall 
in the WBC, RBC and Hb count in DAL mice and CP 
treated mice compared to healthy control mice. A 
moderate improvement in WBC, RBC and Hb count was 
observed in AL (100mg/kg, 200mg/kg) and Amifostine 
treated mice but changes were not significant as 
compared to control group. 
Figure 4 summaries, the changes in the reduced 
glutathione levels in blood. There was significant 
decrease (p<0.05) in blood glutathione level in tumor 
bearing mice and CP treated mice compared to naive 
group. In AL 100mg/kg, 200mg/kg and Amifostine 
pretreated groups, blood GSH level was also 
significantly increased (p<0.05) with respect to naive 
group. Blood GSH level was not significantly increased 
by pretreatment of CP treated tumor bearing mice 
compared to DAL bearing mice.  
Figure 5 shows, the activities of serum SGPT, SGOT 
and ALP enzymes in all treatment groups. There was a 
significant increase (p<0.05) was observed in tumor 
bearing mice and CP treated tumor bearing mice 
compared to naive group. Amifostine and AL did show 
significant change in SGPT, SGOT and ALP activities 
compared to CP treated tumor bearing mice.  
Figure 6 Summaries, the changes in the serum total 
thiol, lipid peroxidation and GST levels of animals of all 
groups. There was significant decrease in GST and total 
thiol level in CP treated tumor bearing mice and DAL 
bearing mice (P<0.05) compared to healthy control 
group. AL (100mg/kg, 200 mg/kg) and Amifostine 
treatment with CP in tumor bearing mice showed 
significant increase in serum GST and total thiol level 
compared to DAL bearing mice. Serum MDA level was 
significantly  increased in DAL tumor bearing mice and 
CP treated mice with respect to healthy control group 
(p<0.05) and significant change has been observed by 
AL (100mg/kg, 200 mg/kg) and Amifostine in CP 
treated tumor bearing mice compared to DAL bearing 
mice.  
Figure 7 summaries, the effect of various treatments on 
liver reduced glutathione levels in mice. There was 
significant decrease in reduced glutathione level in 
tumor bearing mice and CP treated tumor bearing mice 
(p<0.05) compared to naive group. AL (100mg/kg, 200 
mg/kg) and Amifostine showed any significant increase 
in hepatic tissue GSH level compared to DAL bearing 
mice. 
In Figure 8 the effect of various treatments on hepatic 
reduced MDA levels in mice. lipid peroxidation 
increased significantly in DAL bearing mice and CP 
treated tumor bearing mice compared to naïve group 
(p<0.05). MDA level was decreased significantly AL 
(100mg/kg, 200 mg/kg) and Amifostine pretreated tumor 
bearing groups compared to DAL bearing control mice.  
Figure 9 shows the effect of pretreatment of AL and 
Amifostine on catalase levels in CP treated tumor 
bearing mice. The level of catalse significantly (p<0.05) 
increased in DAL bearing mice and CP treated group 
compared to naïve group. The level of catalse was 
decreased in AL and amifostine preteated tumor bearing 
mice compared to DAL bearing control mice. 
Figure 10 shows effect of pretreatment of AL and 
Amifostine on total protein levels in CP treated tumor 
bearing mice. The level of total protein significantly 
(p<0.05) decreased in DAL bearing mice and CP treated 
group compared to naïve group. The level of total 
protein was decreased in AL and amifostine preteated 
tumor bearing mice compared to DAL bearing control 
mice. 
Figure 11 shows the effect of pretreatment of AL 
Amifostine on SOD levels in CP treated tumor bearing 
mice. The level of SOD significantly (p<0.05) decreased 
in DAL bearing mice and CP treated group compared to 
naïve group. The level of SOD was decreased in AL and 
amifostine preteated tumor bearing mice compared to 
DAL bearing control mice. 
Figure 12 shows, the expression of P
53
 protein in liver 
of animals of various treatment groups. The western blot 
indicated that tumor results in the activation of P
53 
protein in liver tissue. CP treated groups shows 
significantly reduction in caspase-3 protein band 
intensity compared to tumor bearing mice. In AL 
pretreated group P
53
 protein also activates as compared 
to naive group. AL (100mg/kg, 200 mg/kg) and 
Amifostine treatment group does not show a significant 
reduction in band intensity (c P
53
 expressions) compared 
to tumor bearing mice.  
In Histological evaluation, liver section of control mice 
showed normal cord pattern, hepatic lobule, central 
canal and hepatocytes (Figure13-A). DAL bearing mice 
liver section showed mild vacuolar degeneration of 
hepatocytes and condensation of chromatin material 
indicative of cell death (Figure 13-B). In CP treated 
groups liver section showed abnormal cord and 
rearranged architecture of hepatocytes. Pretreatment 
with AL also showed the dead hepatocyte and feathery 
degeneration (Figure 13 D, E). The liver of CP 
administered mice pretreated Amifostine showed 
minimal to moderate lesions and some hepatocytes with 
granular degeneration (Figure 13-F). 
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Figure 14 indicates the number of apoptotic cells in 
liver section of animals of various groups. The number 
of apoptotic nuclei in the liver of control group was 
around 1 in a unit area (Figure 22-A). In the contrast, the 
numbers of apoptotic cells were observed frequently in 
centrilobular area in DAL group (Figure 14-B) and CP 
(Figure 14-C) and AL and amifostine treated tumor 
bearing mice (Figure 14-D,E,F) compared with control 
group. 
CONCLUSION 
Results concluded that Arisaema leschenaultia blume 
has accorded better protection in CP exposed tumor 
bearing mice. It not only protects the toxic effect of CP 
towards normal cells but also provides protection of 
tumor cells against cytotoxicity of CP. Thus Arisaema 
leschenaultii blume neutralized the cytotoxic effect of 
CP towards normal cells as well as tumor cells. 
FUTURE ASPECTS 
As till date, there is no specific and effective 
cytoprotectants available against the adverse effects of 
chemotherapeutic agent. Therefore, there is need for the 
novel agent, which protects normal tissues from the 
deleterious effects of chemotherapy with the absence of 
tumor protection and tumor growth stimulation 
properties. 
Studies are required on Arisaema Leschnaultii Blume 
and various other plants and synthetic compounds to 
come up as promising cytoprotective agent against 
chemotherapeutic agents. 
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